Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-03-04

Study Completion Date

2025-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

\- There are more emerging infectious diseases recently. Some could affect many people. Some like Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS) are caused by new germs. Sometimes known germs suddenly infect new and large areas, like Ebola. Many of these diseases don t have good treatments available. Researchers may be able to develop a treatment by using antibodies against these infections.

Objective:

\- To collect antibodies from people with high levels of antibodies to the diseases being studied.

Eligibility:

\- Ages 18-70 years old who weigh at least 110 pounds. They may have been infected with or vaccinated for one of the new infections researchers are studying.

Design:

* Participants will be screened with medical history and blood tests. Researchers will determine if the participant can have apheresis.
* Participants will have apheresis. First, they will be interviewed. Then, a needle will be placed in a vein. Blood will be drawn, and a machine will separate the blood cells from the antibodies and protein. The blood cells will then be returned to the participant through another vein. It takes about 60 minutes for the actual collection.
* Participants will be asked to have the procedure at least 3 times. They can participate in up to 20 sessions total as part of this study. There must be at least 7 days between sessions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Blood and Plasma Collection For Use in Future Clinical Trials

NCT01136057

Influenza A Virus Infection

COMPLETED

Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products

NCT02242968

Vaccines Antiviral Agents Immunologic Factors +2 more

COMPLETED

Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

NCT01052480

Influenza A Influenza B

COMPLETED PHASE2

A Pilot Study for Collection of Anti-Influenza A Immune Plasma

NCT00984451

Influenza A Virus Infection Swine Flu

COMPLETED

A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China

NCT02269007

Influenza

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The administration of convalescent plasma is often used for treatment of emerging infectious diseases. This natural history protocol will collect plasma from subjects that were vaccinated to or recovered from an emerging infectious disease of interest, in a manner that the plasma can be given to other subjects as a therapeutic. Any administration of plasma to subjects will be under a separate protocol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Communicable Diseases Communicable Diseases, Emerging Emerging Infectious Diseases Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Volunteers

Collection of Plasma From Subjects That Recovered From or Were Vaccinated To Emerging Infectious Diseases

Plasma

Intervention Type DRUG

Plasma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plasma

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provide written informed consent before initiation of any study procedures
2. Age \>=8 years old, and \<=70 years old
3. History of a known infection or vaccination towards emerging infectious diseases of interest:
* For convalescent subjects, the following criteria must be met:

* At least 28 days since the subject was symptomatic from the infection
* Afebrile (subjective history acceptable) for at least 28 days
* Enrollment must occur within 24 months of illness.
* For vaccinated subjects, the following criteria must be met:

* Subjects must be at least 14 days after vaccination
* If vaccinated on a blinded study, the study must be unblinded and the subject received active product.
* Enrollment must occur within 24 months of the last vaccination.
* (The above represent the minimum criteria - more restrictive criteria may be listed under disease specific criteria noted in Appendix A)

4\) Weight \>=110 pounds (50 kg)

5\) Adequate peripheral venous access for plasma donation (as judged by the examiner)

6\) Willingness to have samples stored

Exclusion Criteria

1. Any sign of active infection (as judged by the investigator), including but not limited

to:
* Subjective or documented fever (\>38 (Infinite)C)
* Cough
* Shortness of breath
* Diarrhea
2. Pregnancy
4. Subjects that have participated in previous plasma collection or other cell component collection procedures within the last 3 months may have restrictions to participation based on the site plasma collection standard operating procedure (SOP). In this scenario, discussion should occur with the blood establishment to ensure eligibility to donate plasma.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes